Anna Orlova

List of Publications by Year in Descending Order

209 papers	6,448 citations	44 h-index	69 g-index
221 ext. papers	7,222 ext. citations	5.7 avg, IF	5.76 L-index

#	Paper	IF	Citations
209	Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands. *Pharmaceutics*, **2022**, 14, 1098	6.4	0
208	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. *Biomedicines*, **2022**, 10, 1293	4.8	0
207	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. *Pharmaceutics*, **2021**, 13,	6.4	1
206	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. *Pharmaceutics*, **2021**, 13,	6.4	2
205	A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers. *Applied Materials Today*, **2021**, 25, 101199	6.6	5
204	Preclinical Evaluation of Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
203	Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. *Pharmaceutics*, **2021**, 13,	6.4	2
202	Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use. *Bulletin of Siberian Medicine*, **2021**, 20, 23-30	0.4	4
201	PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	7
200	Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody Molecules Lu-ABY-271 and Lu-ABY-027: Impact of DOTA Position on ABD Domain. *Pharmaceutics*, **2021**, 13,	6.4	2
199	Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1. *Cancers*, **2021**, 13,	6.6	3
198	Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle. *Biomaterials*, **2021**, 266, 120381	15.6	3
197	Phase I Study of Tc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer. *Journal of Nuclear Medicine*, **2021**, 62, 493-499	8.9	25
196	Preclinical Evaluation of Tc-Labeled GRPR Antagonists maSSS/SES-PEG-RM26 for Imaging of Prostate Cancer. *Pharmaceutics*, **2021**, 13,	6.4	2
195	Comparative Evaluation of Novel Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting. *Cancers*, **2021**, 13,	6.6	6
194	Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [Ga]Ga-NOTA-PEG-RM26. *Scientific Reports*, **2021**, 11, 3631	4.9	4
193	The Use of a Non-Conventional Long-Lived Gallium Radioisotope Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule. *Pharmaceutics*, **2021**, 13,	6.4	4

192	The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. *Seminars in Cancer Biology*, **2021**, 72, 185-197	12.7	6
191	Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. *Cancers*, **2021**, 13,	6.6	4
190	Phase I trial of Tc-(HE)-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer. *Journal of Nuclear Medicine*, **2021**,	8.9	9
189	HER3 PET Imaging: Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to Zr-Labeled Antibody and Antibody-Fragment-Based Tracers. *Cancers*, **2021**, 13,	6.6	2
188	Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
187	Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. *Pharmaceutics*, **2020**, 12,	6.4	4
186	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
185	Affibody Molecules as Targeting Vectors for PET Imaging. *Cancers*, **2020**, 12,	6.6	32
184	Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	4
183	HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. *Pharmaceutics*, **2020**, 12,	6.4	2
182	Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. *EJNMMI Radiopharmacy and Chemistry*, **2020**, 5, 16	5.8	19
181	Radiolabeled GRPR Antagonists for Imaging of Disseminated Prostate Cancer - Influence of Labeling Chemistry on Targeting Properties. *Current Medicinal Chemistry*, **2020**, 27, 7090-7111	4.3	5
180	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. *Cancers*, **2020**, 13,	6.6	7
179	Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. *International Journal of Biological Macromolecules*, **2020**, 145, 216-225	7.9	13
178	Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1. *Molecules*, **2020**, 25,	4.8	6
177	Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model. *Pharmaceutics*, **2020**, 12,	6.4	7
176	Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches. *Scientific Reports*, **2020**, 10, 18148	4.9	2
175	Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting. *Scientific Reports*, **2020**, 10, 20777	4.9	6

174	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer. *Molecules*, **2020**, 25,	4.8	2
173	Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer. *Cancers*, **2019**, 11,	6.6	13
172	Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111. *Scientific Reports*, **2019**, 9, 655	4.9	13
171	Indirect Radioiodination of DARPin G3 Using N-succinimidyl--Iodobenzoate Improves the Contrast of HER2 Molecular Imaging. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	12
170	Selection of the optimal macrocyclic chelators for labeling with In and Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 140, 109-120	5.7	12
169	Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist Lu-DOTAGA-PEG -RM26. *International Journal of Cancer*, **2019**, 145, 3347-3358	7.5	14
168	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake. *Scientific Reports*, **2019**, 9, 6779	4.9	6
167	Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting. *Biomaterials*, **2019**, 203, 73-85	15.6	13
166	Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2. *International Journal of Oncology*, **2019**, 54, 1209-1220	4.4	9
165	Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of Ga-Labeled Tracers. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	15
164	Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart. *Pharmaceutics*, **2019**, 11,	6.4	5
163	Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates. *Cancers*, **2019**, 11,	6.6	6
162	Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer. *Pharmaceutics*, **2019**, 11,	6.4	11
161	Optimal composition and position of histidine-containing tags improves biodistribution of Tc-labeled DARPin G3. *Scientific Reports*, **2019**, 9, 9405	4.9	23
160	Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A. *International Journal of Oncology*, **2019**, 55, 309-319	4.4	7
159	Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26. *Scientific Reports*, **2019**, 9, 17086	4.9	10
158	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. *Scientific Reports*, **2019**, 9, 14907	4.9	9
157	Increase in negative charge of Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. *Scientific Reports*, **2019**, 9, 17710	4.9	10

156	Direct Targeting Options for STAT3 and STAT5 in Cancer. *Cancers*, **2019**, 11,	6.6	29
155	Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 134, 37-48	5.7	15
154	Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. *Molecular Pharmaceutics*, **2019**, 16, 995-1008	5.6	23
153	Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-ZEGFR:2377. *Oncology Reports*, **2019**, 41, 534-542	3.5	3
152	Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe. *Scientific Reports*, **2018**, 8, 2998	4.9	15
151	Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle. *Journal of Nuclear Medicine*, **2018**, 59, 1092-1098	8.9	33
150	Pharmacologic inhibition of STAT5 in acute myeloid leukemia. *Leukemia*, **2018**, 32, 1135-1146	10.7	68
149	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of Tc-labeled anti-EGFR affibody molecules. *Amino Acids*, **2018**, 50, 981-994	3.5	11
148	Molecular design of radiocopper-labelled Affibody molecules. *Scientific Reports*, **2018**, 8, 6542	4.9	10
147	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. *Journal of Nuclear Medicine*, **2018**, 59, 885-891	8.9	71
146	Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label. *Journal of Nuclear Medicine*, **2018**, 59, 93-99	8.9	28
145	Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors. *Contrast Media and Molecular Imaging*, **2018**, 2018, 6930425	3.2	24
144	Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab. *Molecular Pharmaceutics*, **2018**, 15, 3394-3403	5.6	15
143	Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with In and Ga. *Molecular Pharmaceutics*, **2018**, 15, 2674-2683	5.6	12
142	Cyclic versus Noncyclic Chelating Scaffold for Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression. *Molecular Pharmaceutics*, **2018**, 15, 175-185	5.6	24
141	Preclinical Evaluation of [Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors. *Cells*, **2018**, 7,	7.9	13
140	Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model. *Theranostics*, **2018**, 8, 4462-4476	12.1	19
139	Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs. *Cells*, **2018**, 7,	7.9	14

138	Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. *Journal of Controlled Release*, **2018**, 288, 84-95	11.7	29
137	Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. *Scientific Reports*, **2018**, 8, 9643	4.9	8
136	In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. *Scientific Reports*, **2017**, 7, 43118	4.9	16
135	Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with Cu Using NOTA and NODAGA. *Contrast Media and Molecular Imaging*, **2017**, 2017, 8565802	3.2	10
134	High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26. *Contrast Media and Molecular Imaging*, **2017**, 2017, 6873684	3.2	21
133	Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression. *International Journal of Oncology*, **2017**, 51, 1765-1774	4.4	10
132	The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule. *Scientific Reports*, **2017**, 7, 5961	4.9	27
131	Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m. *Scientific Reports*, **2017**, 7, 14780	4.9	13
130	Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin. *International Journal of Oncology*, **2016**, 49, 1185-94	4.4	21
129	Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX. *Molecular Pharmaceutics*, **2016**, 13, 3676-3687	5.6	24
128	Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator. *International Journal of Oncology*, **2016**, 49, 2285-2293	4.4	21
127	Influence of the N-Terminal Composition on Targeting Properties of Radiometal-Labeled Anti-HER2 Scaffold Protein ADAPT6. *Bioconjugate Chemistry*, **2016**, 27, 2678-2688	6.3	12
126	Synthesis of C-labeled Sulfonyl Carbamates through a Multicomponent Reaction Employing Sulfonyl Azides, Alcohols, and [C]CO. *ChemistryOpen*, **2016**, 5, 566-573	2.3	13
125	Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins. *Bioconjugate Chemistry*, **2016**, 27, 716-26	6.3	31
124	Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting. *Journal of Nuclear Medicine*, **2016**, 57, 431-6	8.9	44
123	Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. *International Journal of Oncology*, **2016**, 48, 2124-34	4.4	20
122	Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules. *Molecular Pharmaceutics*, **2016**, 13, 1668-78	5.6	28
121	Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors. *Theranostics*, **2016**, 6, 93-103	12.1	46

120	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT. *Theranostics*, **2016**, 6, 262-71	12.1	146
119	PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. *International Journal of Oncology*, **2016**, 48, 1325-32	4.4	41
118	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients. *Journal of Nuclear Medicine*, **2016**, 57, 867-71	8.9	69
117	Comparing the measured affinity of 111In-labeled ligands for cellular receptors by monitoring gamma, beta, or X-ray radiation with three different LigandTracer devices. *Journal of Radioanalytical and Nuclear Chemistry*, **2015**, 304, 823-828	1.5	4
116	Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients. *Oncology Letters*, **2015**, 9, 950-954	2.6	5
115	ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers. *Cancer Research*, **2015**, 75, 4364-71	10.1	47
114	Affibody-mediated PET imaging of HER3 expression in malignant tumours. *Scientific Reports*, **2015**, 5, 15226	4.9	51
113	Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity. *ChemistryOpen*, **2015**, 4, 174-82	2.3	10
112	Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors. *Oncology Reports*, **2015**, 34, 1042-8	3.5	25
111	Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. *Amino Acids*, **2015**, 47, 303-15	3.5	19
110	The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26. *Nuclear Medicine and Biology*, **2015**, 42, 446-454	2.1	40
109	Methods for radiolabelling of monoclonal antibodies. *Methods in Molecular Biology*, **2014**, 1060, 309-30	1.4	26
108	Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde. *Bioconjugate Chemistry*, **2014**, 25, 82-92	6.3	24
107	Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. *Cancer Immunology Research*, **2014**, 2, 80-90	12.5	55
106	Gallium-68-labeled affibody molecule for PET imaging of PDGFR expression in vivo. *Molecular Pharmaceutics*, **2014**, 11, 3957-64	5.6	34
105	Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re. *European Journal of Medicinal Chemistry*, **2014**, 87, 519-28	6.8	13
104	Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 1450-9	8.8	38
103	Imaging of platelet-derived growth factor receptor expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591. *Journal of Nuclear Medicine*, **2014**, 55, 294-300	8.9	40

102	Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates. *Molecular Imaging*, **2014**, 13,	3.7	11
101	In vitro modeling of HER2-targeting therapy in disseminated prostate cancer. *International Journal of Oncology*, **2014**, 45, 2153-8	4.4	5
100	The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin. *Molecules*, **2014**, 19, 10455-72	4.8	46
99	Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. *International Journal of Oncology*, **2014**, 44, 1998-2008	4.4	13
98	188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. *Journal of Nuclear Medicine*, **2014**, 55, 1842-8	8.9	20
97	Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes. *PLoS ONE* , **2014**, 9, e107483	3.7	14
96	Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine. *Current Pharmaceutical Design*, **2014**, 20, 2275-92	3.3	13
95	Detecting ligand interactions with G protein-coupled receptors in real-time on living cells. *Biochemical and Biophysical Research Communications*, **2013**, 441, 820-4	3.4	8
94	Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. *Journal of Nuclear Medicine*, **2013**, 54, 961-8	8.9	69
93	Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging. *Nuclear Medicine and Biology*, **2013**, 40, 378-86	2.1	12
92	[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. *European Journal of Nuclear Medicine and Molecular Imaging*, **2013**, 40, 439-49	8.8	31
91	In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors. *Cancer Biotherapy and Radiopharmaceuticals*, **2013**, 28, 187-95	3.9	28
90	HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules. *Journal of Medicinal Chemistry*, **2013**, 56, 4966-74	8.3	47
89	Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with □a and □□n via maleimido derivatives of DOTA and NODAGA. *Bioconjugate Chemistry*, **2013**, 24, 1102-9	6.3	37
88	Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging. *Bioconjugate Chemistry*, **2013**, 24, 1144-53	6.3	56
87	Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts. *PLoS ONE*, **2013**, 8, e70028	3.7	44
86	In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging. *PLoS ONE*, **2013**, 8, e81932	3.7	40
85	Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. *PLoS ONE*, **2013**, 8, e62791	3.7	51

84	Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. *European Journal of Nuclear Medicine and Molecular Imaging*, **2012**, 39, 481-92	8.8	35
83	Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. *Journal of Nuclear Medicine*, **2012**, 53, 953-60	8.9	61
82	Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules. *Bioconjugate Chemistry*, **2012**, 23, 1661-70	6.3	30
81	Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA. *Nuclear Medicine and Biology*, **2012**, 39, 518-29	2.1	12
80	Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. *Drug Discovery Today*, **2012**, 17, 1224-32	8.8	55
79	Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. *Tumor Biology*, **2012**, 33, 641-51	2.9	17
78	Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging. *European Journal of Nuclear Medicine and Molecular Imaging*, **2012**, 39, 693-702	8.8	9
77	Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules. *Amino Acids*, **2012**, 42, 1975-85	3.5	14
76	Protein interactions with HER-family receptors can have different characteristics depending on the hosting cell line. *International Journal of Oncology*, **2012**, 40, 1677-82	4.4	17
75	Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551. *Journal of Nuclear Medicine*, **2012**, 53, 90-7	8.9	41
74	Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I. *Journal of Medicinal Chemistry*, **2011**, 54, 3817-26	8.3	43
73	Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate. *Nuclear Medicine and Biology*, **2011**, 38, 697-706	2.1	8
72	Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody. *Nuclear Medicine and Biology* **2011**, 38, 1093-102	2.1	26
71	Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A?DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. *Experimental and Therapeutic Medicine*, **2011**, 2, 523-528	2.1	21
70	Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab. *International Journal of Oncology*, **2011**, 38, 1137-43	4.4	11
69	Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. *European Journal of Nuclear Medicine and Molecular Imaging*, **2011**, 38, 531-9	8.8	42
68	Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules. *Bioconjugate Chemistry*, **2011**, 22, 894-902	6.3	25
67	Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. *Journal of Nuclear Medicine*, **2011**, 52, 461-9	8.9	68

66	Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. *Journal of Nuclear Medicine*, **2010**, 51, 892-7	8.9	233
65	Preparation and in vitro evaluation of 111In-CHX-A"-DTPA-labeled anti-VEGF monoclonal antibody bevacizumab. *Human Antibodies*, **2010**, 19, 107-11	1.3	10
64	Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. *Current Medicinal Chemistry*, **2010**, 17, 2636-55	4.3	59
63	HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [□□(m)Tc(CO)□](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. *Bioconjugate Chemistry*, **2010**, 21, 2013-22	6.3	63
62	Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. *Lancet Oncology, The*, **2010**, 11, 992-1000	21.7	88
61	Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. *Journal of Nuclear Medicine*, **2010**, 51, 1131-8	8.9	73
60	Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. *International Journal of Oncology*, **2010**, 36, 757-63	4.4	25
59	(186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. *European Journal of Nuclear Medicine and Molecular Imaging*, **2010**, 37, 260-9	8.8	37
58	Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. *European Journal of Nuclear Medicine and Molecular Imaging*, **2010**, 37, 613-22	8.8	97
57	A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. *European Journal of Nuclear Medicine and Molecular Imaging*, **2010**, 37, 1356-67	8.8	71
56	Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors. *Molecular Imaging and Biology*, **2010**, 12, 54-62	3.8	31
55	Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. *Journal of Nuclear Medicine*, **2009**, 50, 274-83	8.9	91
54	Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody. *Biopolymers*, **2009**, 92, 116-23	2.2	14
53	Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 692-701	8.8	47
52	The influence of Bz-DOTA and CHX-A"DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 1460-8	8.8	26
51	Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. *European Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 36, 1864-73	8.8	40
50	Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 3912-4	2.9	16
49	On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. *Journal of Nuclear Medicine*, **2009**, 50, 417-25	8.9	124

48	Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. *Journal of Nuclear Medicine*, **2009**, 50, 781-9	8.9	90
47	Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. *Journal of Molecular Biology*, **2008**, 376, 1388-402	6.5	118
46	Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. *Cancer Biotherapy and Radiopharmaceuticals*, **2008**, 23, 435-42	3.9	99
45	Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. *Bioconjugate Chemistry*, **2008**, 19, 2568-76	6.3	41
44	Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. *Bioconjugate Chemistry*, **2008**, 19, 235-43	6.3	76
43	Evaluation of a maleimido derivative of CHX-A''DTPA for site-specific labeling of affibody molecules. *Bioconjugate Chemistry*, **2008**, 19, 1579-87	6.3	23
42	Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. *European Journal of Nuclear Medicine and Molecular Imaging*, **2008**, 35, 2245-55	8.8	58
41	(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. *Bioconjugate Chemistry*, **2007**, 18, 1956-64	6.3	88
40	Update: affibody molecules for molecular imaging and therapy for cancer. *Cancer Biotherapy and Radiopharmaceuticals*, **2007**, 22, 573-84	3.9	50
39	Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. *Expert Opinion on Biological Therapy*, **2007**, 7, 555-68	5.4	106
38	Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. *European Journal of Nuclear Medicine and Molecular Imaging*, **2007**, 34, 722-733	8.8	76
37	99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. *European Journal of Nuclear Medicine and Molecular Imaging*, **2007**, 34, 1843-53	8.8	69
36	Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. *Cancer Research*, **2007**, 67, 2178-86	10.1	161
35	Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. *International Journal of Molecular Medicine*, **2007**, 19, 285	4.4	3
34	Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. *Cancer Research*, **2007**, 67, 2773-82	10.1	179
33	In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules. *Bioconjugate Chemistry*, **2007**, 18, 549-58	6.3	51
32	Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. *International Journal of Molecular Medicine*, **2007**, 19, 285-91	4.4	25
31	Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand. *International Journal of Molecular Medicine*, **2007**, 19, 485-93	4.4	7

30	Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. *International Journal of Molecular Medicine*, **2007**, 20, 397-404	4.4	20
29	Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 631-8	8.8	58
28	Tumor imaging using a picomolar affinity HER2 binding affibody molecule. *Cancer Research*, **2006**, 66, 4339-48	10.1	405
27	Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. *Journal of Nuclear Medicine*, **2006**, 47, 512-9	8.9	63
26	Radio-iodination of monoclonal antibody using potassium [125I]-(4-isothiocyanatobenzylammonio)-iodo-decahydro-closo-dodecaborate (iodo-DABI). *Anticancer Research*, **2006**, 26, 1217-23	2.3	9
25	111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. *Journal of Nuclear Medicine*, **2006**, 47, 846-53	8.9	72
24	An aminoacridine derivative for radionuclide therapy: DNA binding properties studied in a novel cell-free in vitro assay **2005**, 27, 1355		
23	Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. *Nuclear Medicine and Biology*, **2005**, 32, 613-22	2.1	21
22	Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. *Bioconjugate Chemistry*, **2005**, 16, 1547-55	6.3	47
21	In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma. *Cancer Biotherapy and Radiopharmaceuticals*, **2005**, 20, 514-23	3.9	9
20	[99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluation. *Oncology Reports*, **2005**, 13, 1169-75	3.5	10
19	Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker. *Acta Oto-Laryngologica*, **2004**, 124, 1078-85	1.6	5
18	[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma. *Cancer Biotherapy and Radiopharmaceuticals*, **2004**, 19, 195-204	3.9	10
17	Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice. *Cancer Biotherapy and Radiopharmaceuticals*, **2004**, 19, 491-501	3.9	11
16	Radioiodination of ammonio-closo-monocarborane, 1-H3N-1-CB11H11. Aspects of labelling chemistry in aqueous solution using Chloramine-T. *Radiochimica Acta*, **2004**, 92, 311-315	1.9	2
15	Copper-mediated isotopic exchange between [125I]iodide and bis(triethylammonium) undecahydro-12-iodo-closo-dodecaborate in aqueous media. *Journal of Radioanalytical and Nuclear Chemistry*, **2004**, 260, 295-299	1.5	5
14	Synthesis and Radioiodination of Some 9-Aminoacridine Derivatives. *European Journal of Organic Chemistry*, **2004**, 2004, 3719-3725	3.2	5
13	Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in Normal Mice. *Cancer Biotherapy and Radiopharmaceuticals*, **2004**, 19, 491-501	3.9	13

12	Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells. *Anticancer Research*, **2004**, 24, 4035-41	2.3	7
11	Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides. *Current Medicinal Chemistry*, **2003**, 10, 2447-60	4.3	37
10	Feasibility of isotopic exchange in the system [125I] iodide - undecahydro-iodo-closo-dodecaborate(2-) anion. *Journal of Radioanalytical and Nuclear Chemistry*, **2003**, 256, 67-71	1.5	5
9	Combined effect of gefitinib (IressaR, ZD1839) and targeted radiotherapy with 211At-EGF. *European Journal of Nuclear Medicine and Molecular Imaging*, **2003**, 30, 1348-56	8.8	23
8	[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agent. *Cancer Biotherapy and Radiopharmaceuticals*, **2003**, 18, 643-54	3.9	15
7	Preparation of [76Br] 5-bromo-2-thiouracil, a positron-emitting melanoma localizing agent. *Journal of Radioanalytical and Nuclear Chemistry*, **2002**, 251, 409-412	1.5	2
6	Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry. *Cancer Biotherapy and Radiopharmaceuticals*, **2002**, 17, 385-96	3.9	12
5	Closo-dodecaborate (2-) anion as a potential prosthetic group for attachment of astatine to proteins. Aspects of the labelling chemistry with chloramine-T. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2000**, 43, 251-260	1.9	15
4	Optimization of Iodination of [125I]-N-Succinimidyl-Para-Iodobenzoate Using Chloramine-T for Labeling of Proteins. *Journal of Radioanalytical and Nuclear Chemistry*, **2000**, 246, 207-213	1.5	3
3	Cellular processing of (125)I- and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. *Nuclear Medicine and Biology*, **2000**, 27, 827-35	2.1	34
2	Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET. *Nuclear Medicine and Biology*, **2000**, 27, 837-43	2.1	22
1	Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution. *Bioconjugate Chemistry*, **1999**, 10, 338-45	6.3	29